Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Newly Diagnosed Glioblastoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
      Pathologically confirmed diagnosis of glioblastoma of the cerebrum.
    1. Have a Karnofsky performance status = 70 (i.e., the patient must be able to care for him/herself with occasional help from others).
    2. The result of tumor MGMT me

You may not be eligible for this study if the following are true:

    1. Recurrent or progressive glioblastoma.
    2. Gliosarcoma, anaplastic astrocytoma, oligodendroglioma, ependymoma, low grade glioma or any histology other than glioblastoma.
    3. Multicentric glioblastoma or glioblastoma involvin

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.